top of page
Completed

NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Myeloma RRMM - Myeloma X Relapse


Myeloma X Relapse

NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Multiple Myeloma RRMM - Myeloma X Relapse

Time Frame: April 16, 2008, and Nov 19, 2012


Myeloma X Relapse

Myeloma X Relapse

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy



Sponsor

Leeds Cancer Centre at St. James's University Hospital


Information provided by

National Cancer Institute (NCI)


 

ClinicalTrials.gov Identifier: NCT00747877

Official Title: Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue.

First Posted: September 5, 2008


Click here for details on ClinicalTrials.gov

 

Drug: cyclophosphamide

Drug: melphalan

Procedure: autologous hematopoietic stem cell transplantation

 

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

Lancet Oncol;2014




The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Lancet Haematol;2016



Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial

Biol Blood Marrow Transplant;2016


Click here for details

https://pubmed.ncbi.nlm.nih.gov/26827659/


 

Location

United Kingdom




Posts Archive
bottom of page